Medigen debate is a wake-up call - Taipei Times
The COVID-19 vaccine developed by Taiwan’s Medigen Vaccine Biologics Co has been available to the public since last week, based on an emergency use authorization by the Food and Drug Administration. That it has been authorized before the completion of phase 3 clinical trials has sparked debate. Those opposed to the vaccine’s early approval argue that not waiting for data from phase 3 clinical trials goes against medical ethics, as it leaves people without sufficient data about the vaccine’s full effects on their body. To assess whether the approval process was safe, it is important to ...